Product Description
Benznidazole is an orally available, broad spectrum antimicrobial agent used in the treatment of Chagas disease. Benznidazole is a nitroimidazole similar to metronidazole and is associated with serum enzyme elevations during therapy in up to 10% of patients but has not linked to cases of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Benznidazole)
Mechanisms of Action: DNA Synthesis Inhibitor,RNA Synthetase Inhibitor,Protein Synthesis Inhibitor,NTR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Brazil | Chile | Colombia | Dominican Republic | United Kingdom | United States
Approved Indications: Chagas Disease | Trypanosomiasis
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Urticaria | Eosinophilia | Neutropenia | Pruritus
Company: Exeltis France
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Bolivia, Colombia
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Chagas Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LPRI747-301 | P3 |
Active, not recruiting |
Chagas Disease |
2027-08-30 |
90% |
| NuestroBen | P3 |
Recruiting |
Chagas Disease |
2026-06-01 |
68% |
| MULTBENZ | P2 |
Active, not recruiting |
Chagas Disease |
2018-04-16 |